CL2014001663A1 - Metodo para tratar una enfermedad desmielinizante tal como esclerosis multiple que comprende administrar compuestos andrografolidos y una interferona; y su uso para tratar una enfermedad desmielinizante tal como esclerosis multiple. - Google Patents
Metodo para tratar una enfermedad desmielinizante tal como esclerosis multiple que comprende administrar compuestos andrografolidos y una interferona; y su uso para tratar una enfermedad desmielinizante tal como esclerosis multiple.Info
- Publication number
- CL2014001663A1 CL2014001663A1 CL2014001663A CL2014001663A CL2014001663A1 CL 2014001663 A1 CL2014001663 A1 CL 2014001663A1 CL 2014001663 A CL2014001663 A CL 2014001663A CL 2014001663 A CL2014001663 A CL 2014001663A CL 2014001663 A1 CL2014001663 A1 CL 2014001663A1
- Authority
- CL
- Chile
- Prior art keywords
- multiple sclerosis
- demyelinating disease
- interferon
- administering
- treat
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161578650P | 2011-12-21 | 2011-12-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2014001663A1 true CL2014001663A1 (es) | 2015-02-27 |
Family
ID=48669439
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2014001663A CL2014001663A1 (es) | 2011-12-21 | 2014-06-20 | Metodo para tratar una enfermedad desmielinizante tal como esclerosis multiple que comprende administrar compuestos andrografolidos y una interferona; y su uso para tratar una enfermedad desmielinizante tal como esclerosis multiple. |
Country Status (10)
Country | Link |
---|---|
US (1) | US9060994B2 (es) |
EP (1) | EP2670406B1 (es) |
JP (1) | JP5936707B2 (es) |
AU (1) | AU2012359081B2 (es) |
BR (1) | BR112014015178A2 (es) |
CA (1) | CA2853779C (es) |
CL (1) | CL2014001663A1 (es) |
ES (1) | ES2554459T3 (es) |
RU (1) | RU2014113967A (es) |
WO (1) | WO2013096423A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6928963B2 (ja) * | 2016-06-08 | 2021-09-01 | イノバイオサイエンス, エルエルシー | アンドログラホリドが進化型の多発性硬化症を処置する |
US11318153B2 (en) | 2018-06-25 | 2022-05-03 | Bialpha International Sdn. Bhd. | Method of using Neoandrographolide for lowering blood sugar, lowering blood lipid, improving liver function and improving renal function |
CN109824655B (zh) * | 2019-04-08 | 2021-09-24 | 沈阳药科大学 | 穿心莲内酯化合物及其制备方法和用途 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1043027A1 (en) * | 1999-04-08 | 2000-10-11 | Applied Research Systems ARS Holding N.V. | Treatment of multiple sclerosis with a combination of Interferon and Growth hormone |
US6410590B1 (en) | 2000-02-03 | 2002-06-25 | Dr. Reddy's Research Foundation | Compounds having antitumor activity: process for their preparation and pharmaceutical compositions containing them |
US20050181033A1 (en) | 2000-06-29 | 2005-08-18 | Dekker John P.Iii | Method for delivering interferons to the intradermal compartment |
US20030082138A1 (en) | 2001-09-18 | 2003-05-01 | Chiron Corporation | Methods for treating multiple sclerosis |
KR20070026398A (ko) | 2004-02-03 | 2007-03-08 | 우니베르시다드 오스뜨랄 데 칠레 | Ppar-감마 수용체의 활성화에 의한 자가면역 질환 및알츠하이머병의 치료에 유용한, 천심련으로부터 추출된랍단 디테르펜을 포함하는 조성물 |
US20050220764A1 (en) * | 2004-04-01 | 2005-10-06 | Schering Aktiengesellschaft | Higher-doses of interferon-beta for treatment of multiple sclerosis |
US20080108641A1 (en) | 2006-02-08 | 2008-05-08 | Ajami Alfred M | Compounds for treating inflammatory disorders, demyelinating disdorders and cancers |
JP6095366B2 (ja) * | 2009-06-22 | 2017-03-15 | エスケー バイオファーマシューティカルズ カンパニー リミテッド | 疲労を治療又は予防するための方法 |
-
2012
- 2012-12-19 BR BR112014015178A patent/BR112014015178A2/pt not_active Application Discontinuation
- 2012-12-19 ES ES12859754.9T patent/ES2554459T3/es active Active
- 2012-12-19 EP EP12859754.9A patent/EP2670406B1/en active Active
- 2012-12-19 WO PCT/US2012/070568 patent/WO2013096423A1/en active Application Filing
- 2012-12-19 JP JP2014548825A patent/JP5936707B2/ja active Active
- 2012-12-19 AU AU2012359081A patent/AU2012359081B2/en active Active
- 2012-12-19 CA CA2853779A patent/CA2853779C/en active Active
- 2012-12-19 US US13/984,124 patent/US9060994B2/en active Active
- 2012-12-19 RU RU2014113967A patent/RU2014113967A/ru not_active Application Discontinuation
-
2014
- 2014-06-20 CL CL2014001663A patent/CL2014001663A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
BR112014015178A2 (pt) | 2017-06-13 |
NZ625051A (en) | 2016-07-29 |
EP2670406B1 (en) | 2015-09-02 |
CA2853779A1 (en) | 2013-06-27 |
AU2012359081B2 (en) | 2015-09-17 |
ES2554459T3 (es) | 2015-12-21 |
EP2670406A1 (en) | 2013-12-11 |
RU2014113967A (ru) | 2016-02-10 |
US9060994B2 (en) | 2015-06-23 |
US20140301981A1 (en) | 2014-10-09 |
JP5936707B2 (ja) | 2016-06-22 |
WO2013096423A1 (en) | 2013-06-27 |
JP2015500880A (ja) | 2015-01-08 |
EP2670406A4 (en) | 2014-05-28 |
AU2012359081A1 (en) | 2014-06-05 |
CA2853779C (en) | 2016-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2013003358A1 (es) | Uso de un fumarato para preparar un medicamento útil para tratar esclerosis múltiple. | |
BR112015002541A2 (pt) | composto, composição farmacêutica, uso de um composto, e, método para tratamento de hcv em um paciente. | |
CL2013002612A1 (es) | Compuestos derivados de c4-monometil triterpenoides; composicion farmaceutica que los comprende; y metodo para tratar o prevenir una enfermedad o un trastorno. | |
CL2013001947A1 (es) | Composicion farmaceutica que comprende pioglitazona; uso de pioglitazona para tratar alzheimer; composicion que comprende pioglitazona. | |
BR112014010460A2 (pt) | composto, composição farmacêutica, processo para produzir uma composição farmacêutica, método de tratamento, kit e uso de uma composição farmacêutica | |
BR112015011112A2 (pt) | composto oligomérico, oligômero, composição farmacêutica, uso do composto oligomérico, método de síntese de um composto oligomérico e método de tratamento de uma doença. | |
BR112014010391A2 (pt) | composto, composição farmacêutica, processo de produção de uma composição farmacêutica, método de tratamento, kit e uso de uma composição farmacêutica | |
BR112014004103A2 (pt) | auto-injetor para seringa previamente preenchida retrátil | |
CL2013001428A1 (es) | Compuesto que inhibe la actividad del virus de la hepatitis c (hcv); composición farmacéutica que comprende el compuesto; método de tratamiento de hepatitis c. | |
CL2014000183A1 (es) | Formulación farmacéutica que contienen anticuerpos anti-pcsk9; metodo para preparar dicha formulación. | |
MD4589B1 (ro) | Compoziţie farmaceutică cu conţinut de sofosbuvir şi utilizarea acesteia în tratamentul hepatitei virale C | |
CL2011003120A1 (es) | Alimento medico que comprende glicomacropeptido y dos o mas aminoacidos suplementarios; metodo para fabricar dicho alimento medico; y su uso para tratar un desorden metabolico. | |
ECSP14013239A (es) | Composiciones farmacéuticas | |
CL2014000209A1 (es) | Metodo para tratar esclerosis multiple que comprende el uso de laquinimod y acetato de glatiramero y kit que comprende composiciones farmaceuticas conteniendo a ambos compuestos independientemente. | |
BR112014015294A2 (pt) | método cosmétido; de referência de cor, especialmente para implementar método; sistema para implementar o metodo, pacote de software de computador para implementar o método | |
BR112012026570A2 (pt) | composto, composição farmacêutica, uso de um composto, método para o tratamento de um indíviduo e produto combinado | |
CL2014000470A1 (es) | Compuestos derivados del acido 2-oxo-piridin-3-carboxilico; composicion farmaceutica; combinacion; y su uso para tratar o mejorar una infeccion bacteriana. | |
BR112014010545A2 (pt) | composição farmacêutica, método para tratar um paciente infectado com vírus da hepatite c, uso de uma composição | |
BR112012026843A2 (pt) | composição, composição farmacêutica, processo para preparar uma composição farmacêutica, uso de uma composição e método para tratamento de hiv | |
CL2014000541A1 (es) | Citomegalovirus de replicacion defectuosa condicionada; metodo de produccion; composicion que lo comprende; y su uso para tratar una infeccion por citomegalovirus. | |
BR112015008113A2 (pt) | novo processo para preparar compostos para uso no tratamento de câncer. | |
BR112012021476A2 (pt) | composto, processo para preparação do composto, composição farmacêutica compreendendo uma quantidade terapeuticamente eficaz do composto e emprego de tal composto | |
CL2013003206A1 (es) | Uso de compuestos derivados de metil y etil-carboxamidas de trifluorometil-benzotiofenos, en metodos para promover el crecimiento de plantas. | |
CO6870038A2 (es) | Una nueva composición terapéutica que contiene apomorfina como principio activo | |
CL2015000967A1 (es) | Método para mejorar la tolerancia al estrés abiótico en plantas usando un compuesto derivado de carboxamida o tiocarboxamida; y uso de dicho compuesto. |